17.2 Status Epilepticus & Non-Convulsive Status Epilepticus

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

17.2 Status Epilepticus & Non-Convulsive Status Epilepticus

Key Takeaways Explain This Topic AI

The International League Against Epilepsy (ILAE) operational definition of generalized convulsive status epilepticus (GCSE) establishes two critical time thresholds: t1 (5 minutes), indicating when a seizure is abnormally prolonged and emergent therapy must begin; and t2 (30 minutes), marking when continuous ictal activity causes irreversible neuronal necrosis and pharmacoresistance.

Underdosing benzodiazepines is the most frequent clinical error in Phase 1; IV lorazepam (0.1 mg/kg, typically 4 mg) is first-line with IV access, while IM midazolam (10 mg for patients >40 kg) is preferred when IV access is absent based on the RAMPART trial.

The landmark ESETT trial demonstrated therapeutic equivalence across three Phase 2 urgent control agents in benzodiazepine-refractory convulsive status epilepticus: IV levetiracetam (60 mg/kg), IV fosphenytoin (20 mg PE/kg), and IV sodium valproate (40 mg/kg) each achieved approximately 47% seizure termination with comparable safety.

Refractory status epilepticus (Phase 3) requires immediate endotracheal intubation, continuous invasive arterial pressure monitoring, and continuous general anesthetic infusions (propofol, midazolam, or ketamine) titrated to electrographic burst suppression for 24 to 48 hours under continuous EEG (cEEG) guidance.

Propofol infusion syndrome (PRIS) is a lethal complication of prolonged or high-dose (>4-5 mg/kg/h) propofol therapy characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, acute renal failure, and refractory Brugada-pattern arrhythmias; continuous EEG is mandatory in comatose ICU patients to identify non-convulsive status epilepticus (NCSE) via the Salzburg criteria.

Last updated: October 2026

Operational Definitions and Receptor Neurobiology

In 2015, the International League Against Epilepsy (ILAE) established a revised, mechanistic definition of status epilepticus based on a two-dimensional framework: the first dimension represents the time threshold beyond which an ongoing seizure is abnormally prolonged and unlikely to terminate spontaneously ( t 1 t_1 t 1 ​ ), and the second dimension represents the time point beyond which continuous seizure activity produces long-term, irreversible neuronal necrosis and network alteration ( t 2 t_2 t 2 ​ ).

For Generalized Convulsive Status Epilepticus (GCSE) , these operational time points are defined as:

Time Point 1 ( t 1 = 5 minutes t_1 = 5\text{ minutes} t 1 ​ = 5 minutes ) : Normal generalized convulsive seizures terminate spontaneously within 1 to 2 minutes. A convulsive seizure persisting beyond 5 minutes satisfies the operational definition of status epilepticus and mandates the immediate initiation of Phase 1 emergent antiepileptic pharmacotherapy .

Time Point 2 ( t 2 = 30 minutes t_2 = 30\text{ minutes} t 2 ​ = 30 minutes ) : Continuous convulsive seizure activity lasting beyond 30 minutes produces severe, irreversible neuronal cell death (predominantly in the CA1 and CA3 regions of the hippocampus and laminar neocortex) and severe systemic decompensation.

For Non-Convulsive Status Epilepticus (NCSE) , the operational thresholds are longer: t 1 = 10 minutes t_1 = 10\text{ minutes} t 1 ​ = 10 minutes and t 2 = 60 minutes t_2 = 60\text{ minutes} t 2 ​ = 60 minutes .

Molecular Receptor Trafficking and Pharmacoresistance

The rapid transition of self-terminating seizures into refractory status epilepticus is driven by altered trafficking of postsynaptic neurotransmitter receptors:

GABA A \text{GABA}_A GABA A ​ Receptor Internalization : During sustained seizure activity, continuous chloride influx triggers clathrin-dependent endocytosis and internalization of synaptic GABA A \text{GABA}_A GABA A ​ receptors into the intracellular cytoplasm, where they undergo dephosphorylation and lysosomal degradation. Consequently, synaptic inhibitory GABAergic transmission declines exponentially within minutes, rendering the patient rapidly refractory to first-line benzodiazepine therapy .

NMDA/AMPA Receptor Upregulation : Concurrently, intracellular vesicles containing excitatory glutamate receptors (predominantly NMDA \text{NMDA} NMDA and AMPA \text{AMPA} AMPA subtypes) translocate to and incorporate into the postsynaptic membrane. Excessive glutamate release drives continuous, unconstrained intracellular calcium influx, triggering mitochondrial dysfunction, free radical generation, caspase activation, and excitotoxic neuronal necrosis.

Systemic Pathophysiology: Phase 1 vs. Phase 2

Phase 1 Compensation ( 0 − 30 minutes 0-30\text{ minutes} 0 − 30 minutes ) : Intense autonomic sympathetic discharge produces severe tachycardia, hypertension, hyperglycemia, hyperthermia, and massive lactic acidosis. Cerebral blood flow is markedly augmented to meet massive cerebral metabolic oxygen demands ( C M R O 2 CMRO_2 CMR O 2 ​ ).

Phase 2 Decompensation ( > 30 minutes >30\text{ minutes} > 30 minutes ) : Autonomic exhaustion and systemic collapse ensue. Patients develop systemic hypotension, uncoupling of cerebral blood flow from metabolic demand, hyperpyrexia ( > 40 ∘ C >40^\circ\text{C} > 4 0 ∘ C ), severe mixed metabolic and respiratory acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, disseminated intravascular coagulation (DIC), and cardiac dysrhythmias.

Three-Phase Tiered Treatment Algorithm

Successful management of status epilepticus requires a rigid, time-sensitive, three-phase escalation protocol designed to terminate both clinical convulsions and occult electrographic seizures before irreversible injury occurs.

Phase 1: Emergent Initial Therapy ( 0 − 5 Minutes 0 - 5\text{ Minutes} 0 − 5 Minutes )

Benzodiazepines are the uncontested first-line therapy. The choice of agent depends entirely on whether secure intravenous (IV) access is established:

Intravenous Access Present : IV Lorazepam is preferred due to its lower lipophilicity compared to diazepam, resulting in prolonged central nervous system retention and a longer effective anticonvulsant duration (4 to 14 hours). The guideline dose is 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg IV push (typically 4 mg 4\text{ mg} 4 mg bolus infused at 2 mg/min 2\text{ mg/min} 2 mg/min ), which may be repeated once at 5 to 10 minutes if seizures persist.

Intravenous Access Absent : Intramuscular (IM) Midazolam is the first-line standard. The landmark RAMPART trial (Rapid Anticonvulsant Medication Prior to Arrival Trial, NEJM 2012) demonstrated that IM midazolam administered via an autoinjector ( 10 mg 10\text{ mg} 10 mg IM for adults > 40 kg >40\text{ kg} > 40 kg ; 5 mg 5\text{ mg} 5 mg IM for 13 − 40 kg 13-40\text{ kg} 13 − 40 kg ) is non-inferior—and in clinical practice superior—to IV lorazepam in pre-hospital status epilepticus because it eliminates the critical time delays required to establish peripheral venous access.

Alternative Routes : Rectal diazepam ( 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg , max 20 mg 20\text{ mg} 20 mg ) or intranasal midazolam ( 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg , max 10 mg 10\text{ mg} 10 mg ) if IM midazolam cannot be administered.

Warning

Underdosing benzodiazepines is the most common clinical error in the management of status epilepticus. Giving 1 to 2 mg of IV lorazepam to an adult instead of the full 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg ( 4 mg 4\text{ mg} 4 mg ) dose fails to terminate ictal activity, promotes GABA A \text{GABA}_A GABA A ​ receptor internalization, and accelerates progression to refractory status epilepticus.

Phase 2: Urgent Control Therapy ( 5 − 20 Minutes 5 - 20\text{ Minutes} 5 − 20 Minutes )

If seizures persist despite adequate initial benzodiazepine dosing, clinicians must immediately initiate a second-line, non-sedating intravenous antiseizure medication (ASM). In addition, if a benzodiazepine successfully terminates the seizure, an urgent Phase 2 agent should still be administered to maintain seizure control and prevent recurrence.

The ESETT Trial Synthesis (NEJM 2019)

The Established Status Epilepticus Treatment Trial (ESETT) was a multicenter, randomized, double-blind, comparative-effectiveness trial evaluating 384 children and adults with benzodiazepine-refractory convulsive status epilepticus. Patients were randomized to receive one of three non-sedating IV antiseizure regimens:

Levetiracetam : 60 mg/kg 60\text{ mg/kg} 60 mg/kg IV (maximum 4500 mg 4500\text{ mg} 4500 mg ) infused over 10 minutes.

Fosphenytoin : 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg IV (maximum 1500 mg PE 1500\text{ mg PE} 1500 mg PE ) infused at up to 150 mg PE/min 150\text{ mg PE/min} 150 mg PE/min .

Sodium Valproate : 40 mg/kg 40\text{ mg/kg} 40 mg/kg IV (maximum 3000 mg 3000\text{ mg} 3000 mg ) infused over 10 minutes.

Key Findings :

Therapeutic Equivalence : The primary outcome—cessation of status epilepticus and improvement in responsiveness at 60 minutes without rescue therapy—occurred in approximately 47% of patients in the levetiracetam group, 45% in the fosphenytoin group, and 46% in the valproate group. There were no statistically significant differences in efficacy.

Safety Equivalence : Rates of life-threatening hypotension and respiratory depression were equally low (~1% to 3%) across all three arms.

Clinical Selection Considerations :

Levetiracetam : Highly favored for broad availability, rapid 10-minute infusion, absence of hepatic metabolism (cleared renally), and lack of significant cytochrome P450 drug-drug interactions. Avoid in patients with acute psychotic agitation.

Fosphenytoin : Water-soluble prodrug of phenytoin dosed in Phenytoin Equivalents (PE). Unlike phenytoin, it lacks the propylene glycol vehicle, so infusion-site injury and "purple glove syndrome" are much less likely; hypotension and arrhythmias still occur, so cardiac and blood pressure monitoring are required. It can be infused at up to 150 mg PE/min 150\text{ mg PE/min} 150 mg PE/min (three times faster than phenytoin). Contraindicated in sinus bradycardia, sinoatrial block, and second- or third-degree AV block.

Sodium Valproate : Highly effective broad-spectrum agent with minimal cardiovascular toxicity. Strictly contraindicated in patients with acute liver failure, pancreatitis, urea cycle disorders, pregnancy, and known or suspected mitochondrial disorders (specifically POLG mutations , where valproate precipitates fulminant, fatal hepatic necrosis).

Phase 3: Refractory Status Epilepticus (RSE, > 20 − 40 Minutes >20 - 40\text{ Minutes} > 20 − 40 Minutes )

Refractory Status Epilepticus (RSE) is defined as status epilepticus that continues clinically or electrographically despite adequate doses of an initial first-line benzodiazepine and a second-line non-sedating intravenous ASM. Approximately 30% to 40% of status epilepticus cases progress to RSE.

Management of Phase 3 mandates immediate escalation:

Airway Protection : Perform endotracheal intubation with rapid-sequence induction.

Invasive Hemodynamics : Place an indwelling arterial catheter for continuous arterial pressure monitoring, as continuous anesthetic infusions cause significant vasodilation and myocardial depression.

Continuous IV Anesthetic Infusions :

Propofol : Bolus 1 − 2 mg/kg 1-2\text{ mg/kg} 1 − 2 mg/kg over 5 minutes, followed by continuous infusion at 2 − 10 mg/kg/h 2-10\text{ mg/kg/h} 2 − 10 mg/kg/h ( 30 − 150 μ g/kg/min 30-150\ \mu\text{g/kg/min} 30 − 150 μ g/kg/min ). Acts via GABA A \text{GABA}_A GABA A ​ receptor potentiation and NMDA inhibition. Rapid onset and clearance permit rapid neurological wake-up tests.

Midazolam : Bolus 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg , followed by continuous infusion at 0.05 − 2 mg/kg/h 0.05-2\text{ mg/kg/h} 0.05 − 2 mg/kg/h . Rapidly effective, but highly lipophilic; prolonged infusions lead to peripheral tissue saturation, significant accumulation, and tachyphylaxis.

Ketamine : Non-competitive NMDA receptor antagonist. Bolus 1 − 2 mg/kg 1-2\text{ mg/kg} 1 − 2 mg/kg , followed by continuous infusion at 1 − 5 mg/kg/h 1-5\text{ mg/kg/h} 1 − 5 mg/kg/h . Highly advantageous in hemodynamically marginal patients because it stimulates sympathetic tone, and mechanistically targets the upregulated NMDA receptors of prolonged status epilepticus.

Pentobarbital / Thiopental : High-potency barbiturates. Bolus 5 mg/kg 5\text{ mg/kg} 5 mg/kg , followed by continuous infusion at 1 − 5 mg/kg/h 1-5\text{ mg/kg/h} 1 − 5 mg/kg/h . Reserved for severe RSE refractory to propofol/midazolam. Causes profound vasoplegia, myocardial depression requiring high-dose vasopressors, paralytic ileus, infection risk, and prolonged clearance (half-life > 30 − 60 hours >30-60\text{ hours} > 30 − 60 hours ).

Continuous EEG (cEEG) Target and Duration

Continuous EEG monitoring is mandatory during Phase 3. The therapeutic target of continuous anesthetic titration is either complete electrographic seizure cessation or burst suppression (typically targeting an inter-burst interval of 8 to 15 seconds, or a suppression ratio of 80% to 90%).

Once burst suppression is achieved, the anesthetic infusion is maintained for 24 to 48 hours , during which background non-sedating antiepileptic medications are optimized. The continuous anesthetic is then slowly weaned over 12 to 24 hours under continuous EEG observation to detect seizure recrudescence.

Propofol Infusion Syndrome (PRIS)

PRIS is a lethal toxicological complication of propofol that impairs cellular mitochondrial fatty acid oxidation and oxidative phosphorylation. It classically develops when propofol is infused at doses > 4 − 5 mg/kg/h >4-5\text{ mg/kg/h} > 4 − 5 mg/kg/h ( > 67 − 83 μ g/kg/min >67-83\ \mu\text{g/kg/min} > 67 − 83 μ g/kg/min ) for > 48 hours >48\text{ hours} > 48 hours .

Clinical Manifestations : Severe refractory metabolic acidosis, marked hyperlactatemia, rhabdomyolysis (massive creatine kinase elevation, hyperkalemia, acute kidney injury), hepatomegaly, hypertriglyceridemia, and cardiovascular collapse marked by refractory bradycardia, widened QRS, and Brugada-like ST elevations in V 1 − V 3 V_1-V_3 V 1 ​ − V 3 ​ .

Management : Immediate cessation of propofol infusion, transition to an alternative continuous anesthetic (midazolam or ketamine), aggressive supportive hemodynamic management, and early hemodialysis or continuous renal replacement therapy for metabolic acidosis and hyperkalemia.

Phase Timing First-Line Agents Target & Notes

Phase 1: Emergent 0 − 5 min 0-5\text{ min} 0 − 5 min IV Lorazepam ( 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg , max 4 mg 4\text{ mg} 4 mg ); IM Midazolam ( 10 mg 10\text{ mg} 10 mg if > 40 kg >40\text{ kg} > 40 kg ) Stop seizures within 5 min; do not underdose

Phase 2: Urgent 5 − 20 min 5-20\text{ min} 5 − 20 min IV Levetiracetam ( 60 mg/kg 60\text{ mg/kg} 60 mg/kg , max 4500 mg 4500\text{ mg} 4500 mg ); IV Fosphenytoin ( 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg , max 1500 mg PE 1500\text{ mg PE} 1500 mg PE ); IV Valproate ( 40 mg/kg 40\text{ mg/kg} 40 mg/kg , max 3000 mg 3000\text{ mg} 3000 mg ) All 3 agents clinically equivalent (~47% efficacy) per ESETT trial

Phase 3: Refractory > 20 − 40 min >20-40\text{ min} > 20 − 40 min IV Propofol ( 2 − 10 mg/kg/h 2-10\text{ mg/kg/h} 2 − 10 mg/kg/h ); IV Midazolam ( 0.05 − 2 mg/kg/h 0.05-2\text{ mg/kg/h} 0.05 − 2 mg/kg/h ); IV Ketamine ( 1 − 5 mg/kg/h 1-5\text{ mg/kg/h} 1 − 5 mg/kg/h ); IV Pentobarbital ( 1 − 5 mg/kg/h 1-5\text{ mg/kg/h} 1 − 5 mg/kg/h ) Intubate; titrate continuous infusion to burst suppression on cEEG for 24-48h; monitor for PRIS

Non-Convulsive Status Epilepticus (NCSE) and Continuous EEG

Non-Convulsive Status Epilepticus (NCSE) represents electrographic status epilepticus in the absence of generalized tonic-clonic convulsions. It is exceedingly common in the critical care unit: continuous EEG studies find nonconvulsive seizures or NCSE in roughly 10% to 20% of comatose ICU patients without overt motor activity (higher in some cohorts) following cardiac arrest, severe traumatic brain injury, acute intracerebral hemorrhage, or treated convulsive status epilepticus.

Clinical Presentation and Salzburg Criteria

NCSE presents subtly as unexplained coma, prolonged stupor, fluctuating delirium, abulia, wandering gaze, or discrete micro-movements (subtle perioral twitching, eyelid fluttering, nystagmoid jerking). Accurate diagnosis requires continuous video-EEG (cEEG) evaluated using the 2015 Salzburg Criteria .

In patients without pre-existing epileptic encephalopathy, NCSE is diagnosed if cEEG demonstrates:

Epileptiform discharges > 2.5 Hz >2.5\text{ Hz} > 2.5 Hz ; OR

Epileptiform discharges ≤ 2.5 Hz \le 2.5\text{ Hz} ≤ 2.5 Hz OR rhythmic delta/theta activity ( > 0.5 Hz >0.5\text{ Hz} > 0.5 Hz ) PLUS at least one of the following secondary criteria:

Evolution in frequency ( > 1 Hz >1\text{ Hz} > 1 Hz shift), morphology, or spatial distribution over time.

Subtle clinical ictal phenomena occurring concurrently with the EEG discharges.

Rapid clinical and electrographic resolution following an intravenous test dose of a fast-acting, non-sedating antiepileptic drug (e.g., IV levetiracetam, lacosamide, or small-dose lorazepam 1 mg 1\text{ mg} 1 mg ).

Indications for Continuous Video-EEG in the ICU

Persistent coma or failure to regain baseline consciousness within 30 to 60 minutes following termination of convulsive status epilepticus.

Unexplained fluctuating altered mental status or acute neurological deterioration in patients with severe acute brain injury (ICH, SAH, TBI, stroke).

Post-cardiac arrest comatose patients undergoing targeted temperature management (TTM).

Paroxysmal unexplained movements, repetitive gaze deviation, or unexplained autonomic instability (sudden tachycardia, hypertension, pupillary dilation).